Isoniazid Injection Rx
Generic Name and Formulations:
Isoniazid 100mg/mL; soln for IM inj; contains chlorobutanol.
Indications for Isoniazid Injection:
Treatment and prophylaxis of susceptible tuberculosis.
Treatment: 5mg/kg up to 300mg daily in a single dose; or 15mg/kg up to 900mg/day, 2 or 3 times/week. See literature for regimens in patients with pulmonary TB without HIV, pulmonary TB with HIV, patients with extra pulmonary TB, pregnant women with TB, and patients with multi-drug resistant TB. Prevention: >30kg: 300mg/day in a single dose. Malnourished, predisposed to neuropathy: give concomitant pyridoxine.
Treatment: 10–15mg/kg up to 300mg daily in a single dose; or 20–40mg/kg up to 900mg/day, two or three times/week. See literature for regimens in patients with pulmonary TB without HIV, pulmonary TB with HIV, patients with extra pulmonary TB, pregnant women with TB, and patients with multi-drug resistant TB. Prevention: 10mg/kg (up to 300mg daily) in a single dose. Malnourished, predisposed to neuropathy: give concomitant pyridoxine.
Drug-induced hepatitis. Previous isoniazid-associated hepatic injury. Severe adverse reactions to isoniazid (eg, drug fever, chills, arthritis). Acute liver disease of any etiology.
Increased risk of severe or fatal hepatitis; monitor, discontinue if signs of hepatic damage detected. Defer in acute hepatic disease. Alcoholics. Chronic liver disease. Perform LFTs prior to therapy, then periodically as needed. Severe renal dysfunction. >35yrs old. Peripheral neuropathy or conditions predisposing to neuropathy. Injection drug use. Women belonging to minority groups, particularly in the post-partum period. HIV seropositive. Perform eye exams if visual symptoms occur. Neonates. Pregnancy (Cat.C). Nursing mothers.
Concomitant hepatotoxic agents: may cause fatal liver dysfunction. Concomitant alcohol may be associated with higher incidence of isoniazid hepatitis. Monitor prothrombin time with concomitant anticoagulants. May potentiate phenytoin, carbamazepine, theophylline, valproate (adjust dose). May antagonize ketoconazole. May inhibit assays for serum folate and Vit. B12 (consider alternative methods).
Peripheral neuropathy (esp. in slow acetylators), elevated serum transaminases (SGOT; SGPT), bilirubinemia, bilirubinuria, jaundice, hepatitis (may be fatal), nausea, vomiting, epigastric distress, pancreatitis, blood dyscrasias, hypersensitivity reactions (eg, skin eruptions, TEN, DRESS), pyridoxine deficiency, hyperglycemia, pellagra, metabolic acidosis, gynecomastia, rheumatic syndrome, SLE-like syndrome, inj site reactions.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis